Member Info for Davde

@Gpt10 yes DVRG could have got the tech in a firesale of the IP assets if it had gone bust, but as has been discussed before DVRG got the people as well and they are much more difficult to replace. The value you place on any company is subjective to some degree or another, the true test is what does it contribute to profits in the longer term say 5 years to determine if you paid to much, or got it cheap. My vote is currently we got it cheap but time will verify if that view is correct or not!

MWG seems to be contributing well to DVRG revenue streams so do not see a problem. I had no concerns re the terms of the takeover in terms of shares to BOD members, that what happens in business. In the longer term the value of my investment will grow quicker as a consequence.

@Dibs61 I have always used a PE of 8 when calculating ODX valuation ( agree this is my view and others can have a different view), on that basis for every £25m profit ODX makes equates to 100p SP. We will begin to find out what the profits will be for ODX in coming months and the SP will reflect this accordingly.

DVRG have placed an order for MSYS products so it benefits their revenue, not sure about their balance sheet! If the new MSYS team make this company profitable, remember they were on the verge of failing completely, any offer will reflect the current market value at the time. We need to wait and see on that one.

Good to see confirmation of surplus land. Maybe pay off loan and become debt free again!

If people get paid for making positive comments, then there will be others who get paid to make negative you would think! Personally think nobody gets paid as only fools would invest in a company based on what's said on a public bulletin board.

The Cd4 test is not an HIV diagnostic test as far as I know. It measures immune response and is used to determine treatment if I recall.

Would not rule out BT being used in some capacity for Covid but it does need to meet regulatory requirements first. Still think events and cruise industries will be the market. Even if it does not there is still mileage in non covid products. The SP certainly does not reflect it's potential yet.

Orders will flow via the DPS which becomes operational at end of March/early April imv. We may or may not be told the test we are producing before that but not holding my breath on that one.

It has been noticeable in the past few months that many think Covid is going away (ignoring the scientists views) due to the vaccine roll out. Whilst it is true the vaccine is reducing deaths and hospitalisations, it is still unclear the impact on transmission (it will have some impact extent, unkown as yet). As a consequence investors who a few months ago would have rushed into any share that mentioned a covid product are not doing so now to the same extent. Look at travel stocks for example, many investors are going for covid recovery stocks now. The reality is that Covid will be with us for many years and testing will be ongoing. The results for the BT are very encouraging and when approved for use the market may wake up to the potential for DVRG. It could be earlier when the penny drops with people that to attend any mass event you are going to require a valid negative test. The review's due on April 12th into events and travel are likely to indicate testing requirements going forward. Apologies for my long winded opinion as to why the DVRG SP did not rise significantly on the BT evaluation news.
It could also be that many investors do not understand the technology, not just for covid. It a bit like how many fail to understand that DVRG revenues are not solely derived from contracts but for providing services under master and collaborative agreements.

Mugginsthedog you need to read the UK TPP (Target Product Profile) for breath tests issued 3rd March to see regulatory requirements and intended usage of such tests.

sbbtwenty20 I have read the RNS and presentation and think your 500p by xmas is optimistic but would be very happy to be wrong. It will come it's just when that is the question.

Nationalisation is a possibility however it may not be cheaper than subsidy. From an idealogical point of view may also not be acceptable by current government.

@Jadam OK agree figures, just not the sold "most" of his "core" holding statement is the bit I disagree with, but think you concede that, so will leave it there, as beer impRairing BRain!

Not sure I can see where your figures are coming from?

@Jadam "most of his core holding" you got the figures and dates to justify "most" ! He sold 175,000 of his core holding is my interpretation, not most.

If it was a £1.5bn contract it would say that! The number of tests required will be ordered quarterly.

Think the idea that the contract is worth upto £374m a quarter and a minimum of £50m is a not how I read it or the RNS.

The UK Govt TPP for breathe tests says a minimum of 150 positive cases are required for determining the sensitivity level of the test. A further 250 minimum test of negative tests to verify specificity. It is not thousands! The TPP also states the circumstances where the test would be most effective, one of which is mass gatherings. You can read what you want into the RNS but you can see where a market exists for a BT product.

Certainly illustrates that the MNZS SP has the potential to recover, think all agree that. It when it recovers is the issue, MNZS is a global business and whilst UK is making strides to reduce Covid impact, the same is not happening in many countries where rates are rising once again. I personally think it will be 2023 before a full recovery is in place but would happily take 380p or above by xmas but think 500p is a stretch but you never know! What's for sure it will be anything but a smooth ride. It is now over 3 times it low!